Qiagen N.V. (QGEN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in Venlo, Netherlands. Der aktuelle CEO ist Roland Sackers.
QGEN hat IPO-Datum 1996-06-28, 5,700 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $8.61B.
QIAGEN N.V. is a global provider of sample-to-insight solutions that convert biological materials into molecular insights for diagnostic, research, and applied testing applications. The company offers a comprehensive portfolio of consumables, instruments, and bioinformatics services spanning primary and secondary sample processing, nucleic acid purification, PCR analysis, next-generation sequencing, and molecular diagnostics across oncology, infectious disease, and human identification. QIAGEN serves molecular diagnostics laboratories, academic institutions, pharmaceutical companies, and applied testing customers worldwide through its proprietary silica membrane and magnetic bead technologies, as well as integrated platforms for automated molecular analysis. The company maintains strategic partnerships with leading healthcare and biotechnology firms to expand its capabilities and market reach.